Page 19 - 2020-2021-Heroes-Program-Bklt-v1_fa_Neat

ACS honors AstraZeneca and Bristol Myers Squibb for Farxiga (dapagliflozin), a C-aryl
glucoside SGLT2 inhibitor that reduces hyperglycemia, sodium reabsorption, body weight

and blood pressure, while increasing hematocrit and providing cardiac and renal benefits.
The invention of this new class of SGLT2 inhibitors led to a shift in therapeutic strategy in
type-2 diabetes, heart failure with reduced ejection fraction and chronic kidney disease.

Elisabeth Björk
Elisabeth Björk, M.D., Ph.D., Endocrinologist by training, is the SVP and Global Head of the late
phase development for Cardiovascular, Renal and Metabolism and overall accountable for
development strategy and delivery at AstraZeneca. Elisabeth and her team have built a strong
CVRM portfolio based on science and innovations in clinical development.

David Boulton
Dave Boulton, B.Pharm, Ph.D. is a Clinical Pharmacologist who has worked on dapagliflozin since
the first in human studies in 2003. He is currently an Executive Director in the Clinical
Pharmacology and Quantitative Pharmacology Department at AstraZeneca responsible for
Marketed Products and Lifecycle Management in all therapy areas.

Prashant Deshpande
Prashant P. Deshpande received his Ph.D. from State University of New York at Binghamton.
After postdoctoral studies at the University of Tennessee & Memorial Sloan Kettering
Cancer Center, he joined Process Development Department at Bristol Myers Squibb in 1997.
He is currently a Director, Global Product Development & Supply.

#HeroesofChemistry 19